Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Darolutamide and Abemaciclib in High-Risk Prostate Cancer

NCT05617885 is registered in ClinicalTrials.gov with Praful Ravi, MB BCHir, MRCP as lead sponsor.

NCT NCT05617885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05617885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Darolutamide and Abemaciclib in High-Risk Prostate Cancer
Lead sponsor
Praful Ravi, MB BCHir, MRCP
Phase
Phase 1
Overall status
Completed
Start date
August 9, 2023
Completion date
June 1, 2026
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer, non-metastatic prostate cancer, prostate cancer